Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jeanne Varrone"'
Autor:
Edward L. Snyder, Michael E. Sekela, Ian J. Welsby, Yoshiya Toyoda, Mohamed Alsammak, Neel R. Sodha, Thomas M. Beaver, J. Peter R. Pelletier, James D. Gorham, John S. McNeil, Roman M. Sniecinski, Ronald G. Pearl, Gregory A. Nuttall, Ravi Sarode, T. Brett Reece, Alesia Kaplan, Robertson D. Davenport, Tina S. Ipe, Peyman Benharash, Ileana Lopez-Plaza, Richard R. Gammon, Patrick Sadler, John P. Pitman, Kathy Liu, Stanley Bentow, Laurence Corash, Nina Mufti, Jeanne Varrone, Richard J. Benjamin, for the ReCePI study group
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-13 (2023)
Abstract Background Red blood cell (RBC) transfusion is a critical supportive therapy in cardiovascular surgery (CVS). Donor selection and testing have reduced the risk of transfusion-transmitted infections; however, risks remain from bacteria, emerg
Externí odkaz:
https://doaj.org/article/6afcdc33fc664ea1b6806a81a0f891ba
Autor:
Edward L. Snyder, Allison P. Wheeler, Majed Refaai, Claudia S. Cohn, Jessica Poisson, Magali Fontaine, Mary Sehl, Ajay K. Nooka, Lynne Uhl, Philip Spinella, Maly Fenelus, Darla Liles, Thomas Coyle, Joanne Becker, Michael Jeng, Eric A. Gehrie, Bryan R. Spencer, Pampee Young, Andrew Johnson, Jennifer J. O'Brien, Gary J. Schiller, John D. Roback, Elizabeth Malynn, Ronald Jackups, Scott T. Avecilla, Jin‐Sying Lin, Kathy Liu, Stanley Bentow, Ho‐Lan Peng, Jeanne Varrone, Richard J. Benjamin, Laurence M. Corash
Publikováno v:
Transfusion, vol 62, iss 7
BackgroundPlatelet transfusion carries risk of transfusion-transmitted infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to reduce TTI. Pulmonary adverse events (AEs), including transfusion-related acute lung injury and ac
Autor:
John W. Eikelboom, Salim Yusuf, Paul A. Reilly, Jonas Oldgren, Jeff S. Healey, Jeanne Varrone, Hans-Christoph Diener, Stuart J. Connolly, Stefan H. Hohnloser, Kurt Huber, Scott Kaatz, Marco Alings, Maria Grazia Franzosi, Sean Yang, Lars Wallentin, Michael D. Ezekowitz
Publikováno v:
Circulation. 123:2363-2372
Background— Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Ther
Autor:
Jeanne Varrone, Lars Wallentin, Kurt Huber, Maria Grazia Franzosi, Hans-Christoph Diener, Sean Yang, John W. Eikelboom, Jeff S. Healey, Stefan H. Hohnloser, Salim Yusuf, Michael D. Ezekowitz, Jonas Oldgren, Stuart J. Connolly, Paul A. Reilly, Marco Alings, Scott Kaatz
We agree with Drs Govindarajan and Salgado that because dabigatran 110 mg BID is associated with a lower risk of bleeding, it might be preferred over the 150-mg BID dose in patients with atrial fibrillation who are >75 years old and in clinical situa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cef508caa6a0a662faf84fbdf1029e5f
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=84863037405
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=84863037405
Autor:
Amit Parekh, Jeanne Varrone, Stuart J. Connolly, Jonas Oldgren, Ellison Themeles, Salim Yusuf, Paul A. Reilly, Susan Wang, Lars Wallentin, Michael D. Ezekowitz
Publikováno v:
American Heart Journal. 157:805-810.e2
Vitamin K antagonists (VKAs) are effective for stroke prevention in patients with atrial fibrillation (AF) but are difficult to use. Dabigatran etexilate is a prodrug that is rapidly converted to the active direct thrombin inhibitor dabigatran. It is